IRON Stock — Disc Medicine, Inc.

Disc Medicine, Inc. (IRON)

Updated October 16, 2026.

IRON is a Stock. Total return is -81.6% over the past 6.2 years, 227.8 points behind SPY at 146.2%.

Disc Medicine is a clinical-stage biopharmaceutical company developing novel treatments for serious hematologic diseases, with a pipeline focused on modifying biological pathways related to red blood cell formation and iron metabolism. The company does not currently distribute to shareholders. Disc Medicine may appeal to investors seeking exposure to early-stage drug development in the blood disorder treatment space, though shareholders should be aware that clinical-stage companies carry significant development and regulatory risks with no guarantee of commercialization success.

IRON performance versus SPY

Price and return data through 2026-10-16.

Total return is -81.6% over the past 6.2 years, 227.8 points behind SPY at 146.2%. Over the past year its total return — price change plus distributions reinvested — is -23.6%. Its deepest 1-year drawdown was 40.8%.

IRON key facts

Asset type

Stock

Asset class

Equity

Inception date

08/12/2020

Distribution frequency

None

Last close

$56.84 (as of 2026-10-16)

Market cap

$2,182,249,253

Average volume

560577.0

Beta

2.048

Payout ratio

0.0%

EPS

$-6.69

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IRON risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 40.8%.

Who may consider IRON — and who may not

It is a weaker fit for investors who need monthly cash flow (IRON does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on IRON

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions